Abbott Lowers 2026 Comparable Sales-Growth Outlook to About 6%

Abbott lowered its 2026 comparable sales-growth outlook to about 6%, from the 6.5% to 7.5% range reaffirmed in July, while outlining a Nutrition separation targeted to close by the end of 2027. The revised target is a comparable-sales measure that excludes foreign-exchange effects and certain revenue tied to a multiyear agreement. Abbott also narrowed its 2026 adjusted diluted earnings guidance to $5.50 to $5.55 per share, retaining the midpoint of its previous range. Abbott plans to distribute shares of an independent, publicly traded Nutrition company to its shareholders.

Source: TokenPost